Literature DB >> 25375198

Delayed administration of alpha-difluoromethylornithine prevents hippocampus-dependent cognitive impairment after single and combined injury in mice.

Antiño R Allen1, Kirsten Eilertson, Sourabh Sharma, Jennifer Baure, Barrett Allen, David Leu, Susanna Rosi, Jacob Raber, Ting-Ting Huang, John R Fike.   

Abstract

Radiation exposure due to radiological terrorism and military circumstances are a continuing threat for the civilian population. In an uncontrolled radiation event, it is likely that there will be other types of injury involved, including trauma. While radiation combined injury is recognized as an area of great significance, overall there is a paucity of information regarding the mechanisms underlying the interactions between irradiation and other forms of injury, or what countermeasures might be effective in ameliorating such changes. The objective of this study was to determine if difluoromethylornithine (DFMO) could reduce the adverse effects of single or combined injury if administered beginning 24 h after exposure. Eight-week-old C57BL/J6 young-adult male mice received whole-body cesium-137 ((137)Cs) irradiation with 4 Gy. Immediately after irradiation, unilateral traumatic brain injury was induced using a controlled cortical impact system. Forty-four days postirradiation, animals were tested for hippocampus-dependent cognitive performance in the Morris water maze. After cognitive testing, animals were euthanized and their brains snap frozen for immunohistochemical assessment of neuroinflammation (activated microglia) and neurogenesis in the hippocampal dentate gyrus. Our data show that single and combined injuries induced variable degrees of hippocampus-dependent cognitive dysfunction, and when given 24 h post trauma, DFMO treatment ameliorated those effects. Cellular changes including neurogenesis and numbers of activated microglia were generally not associated with the cognitive changes. Further analyses also revealed that DFMO increased hippocampal protein levels of the antioxidants thioredoxin 1 and peroxiredoxin 3 compared to vehicle treated animals. While the mechanisms responsible for the improvement in cognition after DFMO treatment are not yet clear, these results constitute a basis for further development of DFMO as a countermeasure for ameliorating the of risks for cognitive dysfunction in individuals subjected to trauma and radiation combined injury.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25375198      PMCID: PMC4282164          DOI: 10.1667/RR13753.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  43 in total

1.  Peroxynitrite reductase activity of bacterial peroxiredoxins.

Authors:  R Bryk; P Griffin; C Nathan
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 2.  Radiation injury and neurogenesis.

Authors:  Michelle L Monje; Theo Palmer
Journal:  Curr Opin Neurol       Date:  2003-04       Impact factor: 5.710

3.  Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice.

Authors:  Radoslaw Rola; Jacob Raber; Angela Rizk; Shinji Otsuka; Scott R VandenBerg; Duncan R Morhardt; John R Fike
Journal:  Exp Neurol       Date:  2004-08       Impact factor: 5.330

Review 4.  Polyamines: from molecular biology to clinical applications.

Authors:  J Jänne; L Alhonen; P Leinonen
Journal:  Ann Med       Date:  1991-08       Impact factor: 4.709

5.  Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo.

Authors:  Fumiyuki Hattori; Norihito Murayama; Takafumi Noshita; Shinzo Oikawa
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

6.  Extreme sensitivity of adult neurogenesis to low doses of X-irradiation.

Authors:  Shinichiro Mizumatsu; Michelle L Monje; Duncan R Morhardt; Radoslaw Rola; Theo D Palmer; John R Fike
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

7.  A novel role for polyamines in adult neurogenesis in rodent brain.

Authors:  Jordane Malaterre; Colette Strambi; Aïcha Aouane; Alain Strambi; Geneviève Rougon; Myriam Cayre
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

8.  Radiation brain injury is reduced by the polyamine inhibitor alpha-difluoromethylornithine.

Authors:  J R Fike; G T Gobbel; L J Marton; T M Seilhan
Journal:  Radiat Res       Date:  1994-04       Impact factor: 2.841

9.  Modification of radiation-induced brain injury by alpha-difluoromethylornithine.

Authors:  G T Gobbel; L J Marton; K Lamborn; T M Seilhan; J R Fike
Journal:  Radiat Res       Date:  1991-12       Impact factor: 2.841

10.  Radiation exposure prior to traumatic brain injury induces responses that differ as a function of animal age.

Authors:  Antiño R Allen; Kirsten Eilertson; Ayanabha Chakraborti; Sourabh Sharma; Jennifer Baure; Julian Habdank-Kolaczkowski; Barrett Allen; Susanna Rosi; Jacob Raber; John R Fike
Journal:  Int J Radiat Biol       Date:  2014-02-06       Impact factor: 2.694

View more
  3 in total

1.  Cognitive impairments following cranial irradiation can be mitigated by treatment with a tropomyosin receptor kinase B agonist.

Authors:  Phillip Yang; David Leu; Keqiang Ye; Chandra Srinivasan; John R Fike; Ting-Ting Huang
Journal:  Exp Neurol       Date:  2016-03-02       Impact factor: 5.330

2.  Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model.

Authors:  Julie E Anderson; Madison Trujillo; Taylor McElroy; Thomas Groves; Tyler Alexander; Frederico Kiffer; Antiño R Allen
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

3.  Assessing the Effects of Redox Modifier MnTnBuOE-2-PyP 5+ on Cognition and Hippocampal Physiology Following Doxorubicin, Cyclophosphamide, and Paclitaxel Treatment.

Authors:  Taylor McElroy; Taurean Brown; Fred Kiffer; Jing Wang; Stephanie D Byrum; Rebecca E Oberley-Deegan; Antiño R Allen
Journal:  Int J Mol Sci       Date:  2020-03-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.